Credit: Ludwig Cancer Research
APRIL 28, 2021, NEW YORK - A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert or de-differentiate to a progenitor, or immature, state of cellular development to spawn highly aggressive tumors that are capable of metastasis to the liver and lymph nodes.
The study, led by Ludwig Lausanne s Douglas Hanahan and published in
Cancer Discovery, a journal of the American Association for Cancer Research, also shows that engagement of the mechanism is associated with poorer outcomes in patients diagnosed with pancreatic neuroendocrine tumors (PanNETs). Further, its findings provide concrete evidence that such cellular de-differentiation, widely observed across cancer types, is a not merely a random consequence of cancer cells other aberrations.
Rutgers Cancer Institute of New Jersey Leader Elected as a Member to the National Academy of Sciences
Eileen White, PhD
Newswise New Brunswick, N.J., April 27, 2021 – Rutgers Cancer Institute of New Jersey Deputy Director, Chief Scientific Officer, and Associate Director for Basic Research Eileen White, PhD, has been elected to the National Academy of Sciences (NAS). She is among 120 members elected this year in recognition of their distinguished and continuing achievements in original research.
The NAS is a private, non-profit society of distinguished scholars charged with providing independent, objective advice to the nation on matters related to science and technology. Members are elected to the NAS by their peers for their outstanding contributions to science. Election to membership in the NAS is considered one of the highest honors that a scientist can receive.
E-Mail
LOS ANGELES - Patients with advanced colorectal cancer may be spared from a toxic side effect caused by a type of targeted therapy used to treat the cancer with the help of another drug normally used to treat melanoma, according to a study led by researchers at the UCLA Jonsson Comprehensive Cancer Center and Memorial Sloan Kettering Cancer Center.
For the past decade, epidermal growth factor receptor (EGFR) inhibitors have helped prolong the lives of patients with many advanced cancers, including cancers in the lung, head and neck, colorectal, breast, bladder and pancreas. While these targeted therapy drugs are highly effective at keeping the cancer at bay, they can cause patients to develop acneiform lesions, a type of skin rash that looks like acne bumps and frequently leads to impaired quality of life and drug discontinuation.
Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery
USA - English
LUT014 was found to be safe and effective
LUT014 Phase 2 trial designed to include 117 patients in 20 centers in the US and Israel has been initiated
News provided by
Share this article
Share this article
TEL AVIV, Israel, April 28, 2021 /PRNewswire/ Lutris Pharma, a clinical stage biopharmaceutical company focusing on improving anti-cancer therapies by reducing dose limiting side effects, announced today that results of a Phase1 study for its lead product, LUT014, assessing the safety, tolerability, and efficacy of topically administered LUT014 for the treatment of epidermal growth factor receptor (EGFR) inhibitor-induced acneiform lesions in metastatic colorectal cancer patients, were published in
Date Time
Ludwig Cancer Research study shows pancreatic cancer cells hit reverse to advance in malignancy
APRIL 28, 2021, NEW YORK – A Ludwig Cancer Research study has identified a previously unrecognized mechanism by which cancer cells of a relatively benign subtype of pancreatic tumors methodically revert-or “de-differentiate”-to a progenitor, or immature, state of cellular development to spawn highly aggressive tumors that are capable of metastasis to the liver and lymph nodes.
The study, led by Ludwig Lausanne’s Douglas Hanahan and published in Cancer Discovery, a journal of the American Association for Cancer Research, also shows that engagement of the mechanism is associated with poorer outcomes in patients diagnosed with pancreatic neuroendocrine tumors (PanNETs). Further, its findings provide concrete evidence that such cellular de-differentiation, widely observed across cancer types, is a not merely a random consequence of cancer cells’ other aberrations.